Overview

A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effectiveness of 2 doses of ustekinumab compared with placebo (inactive medication) in adult Japanese participants with severe atopic dermatitis.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.
Treatments:
Ustekinumab